Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients
The steady-state pharmacokinetics and pharmacodynamics of two oral doses of lopinavir-ritonavir (lopinavir/r; 400/100 and 533/133 mg) twice daily (BID) when dosed in combination with efavirenz, plus two nucleoside reverse transcriptase inhibitors, were assessed in a phase II, open-label, randomized,...
Na minha lista:
| Publicado no: | Antimicrob Agents Chemother |
|---|---|
| Principais autores: | , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Microbiology (ASM)
2003
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC148953/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12499212/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.47.1.350-359.2003 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
